Literature DB >> 25002490

Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs.

Dal Young Kim1, Svetlana Atasheva1, Alexander J McAuley2, Jessica A Plante3, Elena I Frolova1, David W C Beasley4, Ilya Frolov5.   

Abstract

Since the development of infectious cDNA clones of viral RNA genomes and the means of delivery of the in vitro-synthesized RNA into cells, alphaviruses have become an attractive system for expression of heterologous genetic information. Alphaviruses replicate exclusively in the cytoplasm, and their genetic material cannot recombine with cellular DNA. Alphavirus genome-based, self-replicating RNAs (replicons) are widely used vectors for expression of heterologous proteins. Their current design relies on replacement of structural genes, encoded by subgenomic RNAs (SG RNA), with heterologous sequences of interest. The SG RNA is transcribed from a promoter located in the alphavirus-specific RNA replication intermediate and is not further amplified. In this study, we have applied the accumulated knowledge of the mechanism of alphavirus replication and promoter structures, in particular, to increase the expression level of heterologous proteins from Venezuelan equine encephalitis virus (VEEV)-based replicons. During VEEV infection, replication enzymes are produced in excess to RNA replication intermediates, and a large fraction of them are not involved in RNA synthesis. The newly designed constructs encode SG RNAs, which are not only transcribed from the SG promoter, but are additionally amplified by the previously underused VEEV replication enzymes. These replicons produce SG RNAs and encoded proteins of interest 10- to 50-fold more efficiently than those using a traditional design. A modified replicon encoding West Nile virus (WNV) premembrane and envelope proteins efficiently produced subviral particles and, after a single immunization, elicited high titers of neutralizing antibodies, which protected mice from lethal challenge with WNV.

Entities:  

Keywords:  expression vectors; vaccines

Mesh:

Substances:

Year:  2014        PMID: 25002490      PMCID: PMC4115546          DOI: 10.1073/pnas.1408677111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Selection of RNA replicons capable of persistent noncytopathic replication in mammalian cells.

Authors:  I Frolov; E Agapov; T A Hoffman; B M Prágai; M Lippa; S Schlesinger; C M Rice
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Cis-acting RNA elements at the 5' end of Sindbis virus genome RNA regulate minus- and plus-strand RNA synthesis.

Authors:  I Frolov; R Hardy; C M Rice
Journal:  RNA       Date:  2001-11       Impact factor: 4.942

3.  Changes of the secondary structure of the 5' end of the Sindbis virus genome inhibit virus growth in mosquito cells and lead to accumulation of adaptive mutations.

Authors:  Rafik Fayzulin; Ilya Frolov
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

4.  The amino-terminal domain of alphavirus capsid protein is dispensable for viral particle assembly but regulates RNA encapsidation through cooperative functions of its subdomains.

Authors:  Valeria Lulla; Dal Young Kim; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

Review 5.  Alphavirus-based expression vectors: strategies and applications.

Authors:  I Frolov; T A Hoffman; B M Prágai; S A Dryga; H V Huang; S Schlesinger; C M Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

6.  Deletion mapping of Sindbis virus DI RNAs derived from cDNAs defines the sequences essential for replication and packaging.

Authors:  R Levis; B G Weiss; M Tsiang; H Huang; S Schlesinger
Journal:  Cell       Date:  1986-01-17       Impact factor: 41.582

7.  18S defective interfering RNA of Semliki Forest virus contains a triplicated linear repeat.

Authors:  P Lehtovaara; H Söderlund; S Keränen; R F Pettersson; L Kääriäinen
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

8.  Extreme ends of the genome are conserved and rearranged in the defective interfering RNAs of Semliki Forest virus.

Authors:  P Lehtovaara; H Söderlund; S Keränen; R F Pettersson; L Kääriäinen
Journal:  J Mol Biol       Date:  1982-04-25       Impact factor: 5.469

Review 9.  The alphaviruses: gene expression, replication, and evolution.

Authors:  J H Strauss; E G Strauss
Journal:  Microbiol Rev       Date:  1994-09

10.  Selection of functional 5' cis-acting elements promoting efficient sindbis virus genome replication.

Authors:  Rodion Gorchakov; Richard Hardy; Charles M Rice; Ilya Frolov
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

View more
  11 in total

1.  Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles.

Authors:  Mariane Melo; Ely Porter; Yuan Zhang; Murillo Silva; Na Li; Brian Dobosh; Alessia Liguori; Pat Skog; Elise Landais; Sergey Menis; Devin Sok; David Nemazee; William R Schief; Ron Weiss; Darrell J Irvine
Journal:  Mol Ther       Date:  2019-08-19       Impact factor: 11.454

Review 2.  Viral and Synthetic RNA Vector Technologies and Applications.

Authors:  Juliane W Schott; Michael Morgan; Melanie Galla; Axel Schambach
Journal:  Mol Ther       Date:  2016-07-05       Impact factor: 11.454

Review 3.  Alphaviruses in gene therapy.

Authors:  Kenneth Lundstrom
Journal:  Viruses       Date:  2015-05-07       Impact factor: 5.048

4.  A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations.

Authors:  Neal Van Hoeven; Sharvari Waghmare Joshi; Ghislain Ismael Nana; Angela Bosco-Lauth; Christopher Fox; Richard A Bowen; David E Clements; Timothy Martyak; D Elliot Parks; Susan Baldwin; Steven G Reed; Rhea N Coler
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

Review 5.  Oncolytic Alphaviruses in Cancer Immunotherapy.

Authors:  Kenneth Lundstrom
Journal:  Vaccines (Basel)       Date:  2017-04-12

6.  Viral replicons as valuable tools for drug discovery.

Authors:  Holger Hannemann
Journal:  Drug Discov Today       Date:  2020-04-06       Impact factor: 7.851

Review 7.  Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases.

Authors:  Nusrat Zahan Rouf; Sumit Biswas; Nawseen Tarannum; Labiba Mustabina Oishee; Mutia Masuka Muna
Journal:  RNA Biol       Date:  2021-12-31       Impact factor: 4.652

8.  New World and Old World Alphaviruses Have Evolved to Exploit Different Components of Stress Granules, FXR and G3BP Proteins, for Assembly of Viral Replication Complexes.

Authors:  Dal Young Kim; Josephine M Reynaud; Aliaksandra Rasalouskaya; Ivan Akhrymuk; James A Mobley; Ilya Frolov; Elena I Frolova
Journal:  PLoS Pathog       Date:  2016-08-10       Impact factor: 6.823

9.  A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen.

Authors:  Neal Van Hoeven; Steven Wiley; Emily Gage; Andrew Fiore-Gartland; Brian Granger; Sean Gray; Christopher Fox; David E Clements; D Elliot Parks; Scott Winram; Dan T Stinchcomb; Steven G Reed; Rhea N Coler
Journal:  NPJ Vaccines       Date:  2018-09-26       Impact factor: 7.344

Review 10.  Advances in COVID-19 mRNA vaccine development.

Authors:  Enyue Fang; Xiaohui Liu; Miao Li; Zelun Zhang; Lifang Song; Baiyu Zhu; Xiaohong Wu; Jingjing Liu; Danhua Zhao; Yuhua Li
Journal:  Signal Transduct Target Ther       Date:  2022-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.